Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Guardant Health, Inc. is placed fifth on our list among the best cancer stocks.

TheFly reported on January 9 that Stifel increased its price target on GH to $120 from $100 while maintaining a Buy rating. The firm anticipates strong volume and average selling price growth in 2026, with publication and reimbursement events that it claims will keep investors interested.

Similarly, on the same day, Mizuho raised its price target on Guardant Health, Inc. (NASDAQ:GH) to $135 from $120 while maintaining an Outperform rating. Additionally, the firm revised its models for the diagnostics and medical device sectors.

Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build

Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company focused on developing non-invasive liquid biopsy tests for cancer detection, treatment selection, and disease monitoring. Its flagship products, including Guardant360 and Guardant Shield, enable early detection, biomarker profiling, and real-time monitoring, supporting personalized cancer care.

While we acknowledge the risk and potential of GH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GH and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.